Phase II evaluation of EMD121974 (NSC 707544, cilengitide) in asymptomatic patients with metastatic androgen independent prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2013
At a glance
- Drugs Cilengitide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 Jul 2012 Actual end date (1 Jan 2011) added as reported by CliniclaTrials.gov.
- 01 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History